Add to my selection

AVASTIN

Medicine - Posted on Jul 19 2018 - Updated on Jun 12 2019

Active substance (DCI)

Bevacizumab

history (17)

7/11/18

AVASTIN (Bevacizumab)

Le laboratoire ne demande pas le remboursement en association à l’erlotinib, en traitement de première ligne chez les patien...

icône flèche
10/11/17

AVASTIN (Bevacizumab)

Le laboratoire ne demande pas le remboursement en association au carboplatine et au paclitaxel, dans le cancer épithélial de...

icône flèche
4/20/16

AVASTIN (bevacizumab), monoclonal antibody

No clinical benefit demonstrated in first-line treatment of metastatic colorectal cancer by comparison with anti-EGFR treatm...

CAV :
54321

icône flèche
6/29/16

AVASTIN (bevacizumab), monoclonal antibody - OVARIAN CANCER

Minor improvement in the treatment of advanced stage ovarian cancer AVASTIN has Marketing Authorisation in combination with ...

CAV :
54321

icône flèche
5/25/16

AVASTIN (bevacizumab), monoclonal antibody

No clinical benefit demonstrated in first-line of non-squamous locally advanced or metastatic non-small cell lung cancer. AV...

CAV :
54321

icône flèche
4/20/16

AVASTIN (bevacizumab), monoclonal antibody

In combination with fluoropyrimidine-based chemotherapy, no clinical benefit demonstrated in second-line treatment of metast...

CAV :
54321

icône flèche

7/6/16

AVASTIN (bevacizumab), monoclonal antibody - CERVICAL CANCER

Minor improvement in the treatment of persistent, recurrent or metastatic cervical cancer AVASTIN has Marketing Authorisatio...

CAV :
54321

icône flèche
3/2/16

AVASTIN (bevacizumab), monoclonal antibody - RENAL CELL CARCINOMA

Significant clinical interest without demonstrated clinical benefit in combination with interferon in the first-line managem...

CAV :
54321

icône flèche
4/13/16

AVASTIN (bevacizumab), monoclonal antibody - BREAST CANCER

Low clinical interest without demonstrated clinical benefit in combination with paclitaxel relative to paclitaxel alone in t...

CAV :
54321

icône flèche
4/1/15

AVASTIN (bevacizumab), monoclonal antibody

No clinical added value demonstrated in treatment of the first recurrence of platinum-sensitive ovarian cancer or the recurr...

CAV :
54321

icône flèche
12/5/12

AVASTIN (Bevacizumab)

Progrès thérapeutique mineur dans le traitement de première ligne des stades avancés du cancer de l’ovaire, du cancer des tr...

CAV :
54321

icône flèche
5/25/11

AVASTIN

-

CAV :
54321

icône flèche
3/4/09

AVASTIN

Progrès thérapeutique mineur en association à une chimiothérapie à base de fluoropyrimidine en deuxième ligne du traitement ...

CAV :
54321

icône flèche
9/3/08

AVASTIN

CANCEROLOGIE – NOUVELLE INDICATION AVASTIN, bevacizumab, anticorps monoclonal qui se lie au VEGF Progrès thérapeutique mineu...

CAV :
54321

icône flèche
5/14/08

AVASTIN

AVASTIN

CAV :
54321

icône flèche
12/5/07

AVASTIN

AVASTIN

CAV :
54321

icône flèche
6/8/05

AVASTIN (Bevacizumab)

AVASTIN (Bevacizumab)

icône flèche

Technical information

ATC code

L01XC07

Manufacturer

ROCHE SAS

Presentation

AVASTIN 25 mg/ml, solution à diluer pour perfusion : 1 flacon en verre de 16 ml - Code CIP : 3400956620135 / 1 flacon en verre de 4 ml - Code CIP : 3400956620074 - (code CIS : 60391646)

All our publications

Breast cancers

Digestive system cancers

Drug therapy

Genital cancers

Health economics

Respiratory tract cancers

Urologic cancers

My account

You do not have a saved search

No element in selection

AVASTIN

AVASTIN (Bevacizumab)

AVASTIN (Bevacizumab)

AVASTIN (bevacizumab), monoclonal antibody

AVASTIN (bevacizumab), monoclonal antibody - OVARIAN CANCER

AVASTIN (bevacizumab), monoclonal antibody

AVASTIN (bevacizumab), monoclonal antibody

AVASTIN (bevacizumab), monoclonal antibody - CERVICAL CANCER

AVASTIN (bevacizumab), monoclonal antibody - RENAL CELL CARCINOMA

AVASTIN (bevacizumab), monoclonal antibody - BREAST CANCER

AVASTIN (bevacizumab), monoclonal antibody

AVASTIN (Bevacizumab)

AVASTIN

AVASTIN

AVASTIN

AVASTIN

AVASTIN

AVASTIN (Bevacizumab)

Follow us :